Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spaepen, K.
Right arrow Articles by Verhoef, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spaepen, K.
Right arrow Articles by Verhoef, G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 2 (January), 2001: 414-419
© 2001 American Society for Clinical Oncology

Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?

By Karoline Spaepen, Sigrid Stroobants, Patrick Dupont, Steven Van Steenweghen, José Thomas, Peter Vandenberghe, Lucien Vanuytsel, Guy Bormans, Jan Balzarini, Christine De Wolf-Peeters, Luc Mortelmans, Gregor Verhoef

From the Departments of Nuclear Medicine, Oncology, Hematology, and Pathology, University Hospital Gasthuisberg and Catholic University of Leuven, Leuven, Belgium.

Address reprint requests to Luc Mortelmans, MD, PhD, Department of Nuclear Medicine, University Hospital Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium; email luc.mortelmans{at}uz.kuleuven.ac.be

PURPOSE: A complete remission (CR) after first-line therapy is associated with longer progression-free survival (PFS). However, defining CR is not always easy because of the presence of residual masses. Metabolic imaging with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET) offers the ability to differentiate between viable and fibrotic inactive tissue. In this study, we evaluated the value of PET in detecting residual disease and, hence, predicting relapse after first-line treatment in patients with non-Hodgkin’s lymphoma (NHL).

PATIENTS AND METHODS: Ninety-three patients with histologically proven NHL, who underwent a whole-body [18F]FDG-PET study after completion of first-line chemotherapy and who had follow-up of at least 1 year, were included. Persistence or absence of residual disease on PET was related to PFS using Kaplan-Meier survival analysis.

RESULTS: Sixty-seven patients showed a normal PET scan after first-line chemotherapy; 56 of 67 remained in CR, with a median follow-up of 653 days. Nine of these patients with a residual mass considered as unconfirmed CR received additional radiotherapy. Only 11 of 67 patients relapsed (median PFS, 404 days). Persistent abnormal [18F]FDG uptake was seen in 26 patients, and all of them relapsed (median PFS, 73 days). Because standard restaging also suggested residual disease, 12 patients received immediate secondary treatment. In 14 of 26 patients, only PET predicted persistent disease. From these patients, relapse was proven either by biopsy (n = 8) or by progressive disease on computed tomography or magnetic resonance imaging (n = 6).

CONCLUSION: Persistent abnormal [18F]FDG uptake after first-line chemotherapy in NHL is highly predictive for residual or recurrent disease. In relapsing patients, PFS was significantly shorter after a positive scan than after a negative scan.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 BloodHome page
T. B. Bartel, J. Haessler, T. L. Y. Brown, J. D. Shaughnessy Jr, F. van Rhee, E. Anaissie, T. Alpe, E. Angtuaco, R. Walker, J. Epstein, et al.
F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma
Blood, September 3, 2009; 114(10): 2068 - 2076.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Bystrom, A. Berglund, U. Garske, H. Jacobsson, A. Sundin, P. Nygren, J.-E. Frodin, and B. Glimelius
Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer
Ann. Onc., June 1, 2009; 20(6): 1057 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. Hutchings and S. F. Barrington
PET/CT for Therapy Response Assessment in Lymphoma
J. Nucl. Med., May 1, 2009; 50(Suppl_1): 21S - 30S.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
E. Itti, C. Lin, J. Dupuis, G. Paone, D. Capacchione, A. Rahmouni, C. Haioun, and M. Meignan
Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy
J. Nucl. Med., April 1, 2009; 50(4): 527 - 533.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Schwarz-Dose, M. Untch, R. Tiling, S. Sassen, S. Mahner, S. Kahlert, N. Harbeck, A. Lebeau, W. Brenner, M. Schwaiger, et al.
Monitoring Primary Systemic Therapy of Large and Locally Advanced Breast Cancer by Using Sequential Positron Emission Tomography Imaging With [18F]Fluorodeoxyglucose
J. Clin. Oncol., February 1, 2009; 27(4): 535 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. S. Han, M. P. Escalon, B. Hsiao, A. Serafini, and I. S. Lossos
High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens
Ann. Onc., February 1, 2009; 20(2): 309 - 318.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
H. A. Jacene, R. Filice, W. Kasecamp, and R. L. Wahl
18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy
J. Nucl. Med., January 1, 2009; 50(1): 8 - 17.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
N. A. Mohile, L. M. DeAngelis, and L. E. Abrey
The utility of body FDG PET in staging primary central nervous system lymphoma
Neuro-oncol, April 1, 2008; 10(2): 223 - 228.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
C. Bodet-Milin, F. Kraeber-Bodere, B. Dupas, F. Morschhauser, T. Gastinne, S. Le Gouill, L. Campion, J.-L. Harousseau, W. A. Wegener, D. M. Goldenberg, et al.
Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography
Haematologica, March 1, 2008; 93(3): 390 - 397.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
S. Sasaki, N. Shikama, K. Koiwai, and M. Kadoya
Relationship Between the Response to Treatment and the Prognosis of Patients with Aggressive Lymphomas Treated with Chemotherapy Followed by Involved-field Radiotherapy: Radiographic Assessment
Jpn. J. Clin. Oncol., January 1, 2008; 38(1): 43 - 48.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. E. Juweid
18F-FDG PET as a Routine Test for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: Where Is the Evidence?
J. Nucl. Med., January 1, 2008; 49(1): 9 - 12.
[Full Text] [PDF]

Home page
 JNMHome page
T. Terasawa, T. Nihashi, T. Hotta, and H. Nagai
18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review
J. Nucl. Med., January 1, 2008; 49(1): 13 - 21.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. K. Schwarz, B. A. Siegel, F. Dehdashti, and P. W. Grigsby
Association of Posttherapy Positron Emission Tomography With Tumor Response and Survival in Cervical Carcinoma
JAMA, November 21, 2007; 298(19): 2289 - 2295.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
P. Seam, M. E. Juweid, and B. D. Cheson
The role of FDG-PET scans in patients with lymphoma
Blood, November 15, 2007; 110(10): 3507 - 3516.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Patte, A. Auperin, M. Gerrard, J. Michon, R. Pinkerton, R. Sposto, C. Weston, M. Raphael, S. L. Perkins, K. McCarthy, et al.
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
Blood, April 1, 2007; 109(7): 2773 - 2780.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid, S. Stroobants, O. S. Hoekstra, F. M. Mottaghy, M. Dietlein, A. Guermazi, G. A. Wiseman, L. Kostakoglu, K. Scheidhauer, A. Buck, et al.
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 571 - 578.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. D. Cheson, B. Pfistner, M. E. Juweid, R. D. Gascoyne, L. Specht, S. J. Horning, B. Coiffier, R. I. Fisher, A. Hagenbeek, E. Zucca, et al.
Revised Response Criteria for Malignant Lymphoma
J. Clin. Oncol., February 10, 2007; 25(5): 579 - 586.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
Y. L. Kasamon, R. J. Jones, and R. L. Wahl
Integrating PET and PET/CT into the Risk-Adapted Therapy of Lymphoma
J. Nucl. Med., January 1, 2007; 48(1_suppl): 19S - 27S.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. E. Juweid and B. D. Cheson
Positron-Emission Tomography and Assessment of Cancer Therapy
N. Engl. J. Med., February 2, 2006; 354(5): 496 - 507.
[Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
O. Mawlawi, J. J. Erasmus, R. F. Munden, T. Pan, A. E. Knight, H. A. Macapinlac, D. A. Podoloff, and M. Chasen
Quantifying the Effect of IV Contrast Media on Integrated PET/CT: Clinical Evaluation
Am. J. Roentgenol., February 1, 2006; 186(2): 308 - 319.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Bibb, R. Hromas, and I. Rabinowitz
A Bayesian Approach to a Patient With a Residual Mass After Treatment for Non-Hodgkin's Lymphoma of the Thyroid
J. Clin. Oncol., December 1, 2005; 23(34): 8911 - 8913.
[Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
W A Weber
PET for response assessment in oncology: radiotherapy and chemotherapy
Br. J. Radiol., November 1, 2005; Supplement_28(1): 42 - 49.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. Avril, S. Sassen, B. Schmalfeldt, J. Naehrig, S. Rutke, W. A. Weber, M. Werner, H. Graeff, M. Schwaiger, and W. Kuhn
Prediction of Response to Neoadjuvant Chemotherapy by Sequential F-18-Fluorodeoxyglucose Positron Emission Tomography in Patients With Advanced-Stage Ovarian Cancer
J. Clin. Oncol., October 20, 2005; 23(30): 7445 - 7453.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. Reinhardt, C. Herkel, C. Altehoefer, J. Finke, and E. Moser
Computed tomography and 18F-FDG positron emission tomography for therapy control of Hodgkin's and non-Hodgkin's lymphoma patients: when do we really need FDG-PET?
Ann. Onc., September 1, 2005; 16(9): 1524 - 1529.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
C. Haioun, E. Itti, A. Rahmouni, P. Brice, J.-D. Rain, K. Belhadj, P. Gaulard, L. Garderet, E. Lepage, F. Reyes, et al.
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
Blood, August 15, 2005; 106(4): 1376 - 1381.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid, G. A. Wiseman, J. M. Vose, J. M. Ritchie, Y. Menda, J. E. Wooldridge, F. M. Mottaghy, E. M. Rohren, N. M. Blumstein, A. Stolpen, et al.
Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., July 20, 2005; 23(21): 4652 - 4661.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. E. Juweid and B. D. Cheson
Role of Positron Emission Tomography in Lymphoma
J. Clin. Oncol., July 20, 2005; 23(21): 4577 - 4580.
[Full Text] [PDF]

Home page
 JNMHome page
W. A. Weber
Use of PET for Monitoring Cancer Therapy and for Predicting Outcome
J. Nucl. Med., June 1, 2005; 46(6): 983 - 995.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al.
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. P. Beal, H. W. Yeung, and J. Yahalom
FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases
Ann. Onc., March 1, 2005; 16(3): 473 - 480.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
J. W. Sweetenham
Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease
Hematology, January 1, 2005; 2005(1): 252 - 259.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
T. Kazama, S. C. Faria, V. Varavithya, S. Phongkitkarun, H. Ito, and H. A. Macapinlac
FDG PET in the Evaluation of Treatment for Lymphoma: Clinical Usefulness and Pitfalls
RadioGraphics, January 1, 2005; 25(1): 191 - 207.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. Israel, M. Mor, L. Guralnik, N. Hermoni, D. Gaitini, R. Bar-Shalom, Z. Keidar, and R. Epelbaum
Is 18F-FDG PET/CT Useful for Imaging and Management of Patients with Suspected Occult Recurrence of Cancer?
J. Nucl. Med., December 1, 2004; 45(12): 2045 - 2051.
[Abstract] [Full Text] [PDF]

Home page
 Med Decis MakingHome page
M. Mazumdar
Group Sequential Design for Comparative Diagnostic Accuracy Studies: Implications and Guidelines for Practitioners
Med Decis Making, October 1, 2004; 24(5): 525 - 533.
[Abstract] [PDF]

Home page
 CA Cancer J ClinHome page
B. D. Cheson
What Is New in Lymphoma?
CA Cancer J Clin, September 1, 2004; 54(5): 260 - 272.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Horning, E. Weller, K. Kim, J. D. Earle, M. J. O'Connell, T. M. Habermann, and J. H. Glick
Chemotherapy With or Without Radiotherapy in Limited-Stage Diffuse Aggressive Non-Hodgkin's Lymphoma: Eastern Cooperative Oncology Group Study 1484
J. Clin. Oncol., August 1, 2004; 22(15): 3032 - 3038.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. M. Rohren, T. G. Turkington, and R. E. Coleman
Clinical Applications of PET in Oncology
Radiology, May 1, 2004; 231(2): 305 - 332.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. De Santis, A. Becherer, C. Bokemeyer, F. Stoiber, K. Oechsle, F. Sellner, A. Lang, K. Kletter, B. M. Dohmen, C. Dittrich, et al.
2-18fluoro-deoxy-D-glucose Positron Emission Tomography Is a Reliable Predictor for Viable Tumor in Postchemotherapy Seminoma: An Update of the Prospective Multicentric SEMPET Trial
J. Clin. Oncol., March 15, 2004; 22(6): 1034 - 1039.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. W. Friedberg and V. Chengazi
PET Scans in the Staging of Lymphoma: Current Status
Oncologist, October 1, 2003; 8(5): 438 - 447.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
J.-E. Filmont, J. Czernin, C. Yap, D. H. S. Silverman, A. Quon, M. E. Phelps, and C. Emmanouilides
Value of F-18 Fluorodeoxyglucose Positron Emission Tomography for Predicting the Clinical Outcome of Patients With Aggressive Lymphoma Prior to and After Autologous Stem-Cell Transplantation
Chest, August 1, 2003; 124(2): 608 - 613.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
C. Guay, M. Lepine, J. Verreault, and F. Benard
Prognostic Value of PET Using 18F-FDG in Hodgkin's Disease for Posttreatment Evaluation
J. Nucl. Med., August 1, 2003; 44(8): 1225 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger
Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use
J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Maertens, G. Bormans, J. Thomas, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, et al.
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
Blood, July 1, 2003; 102(1): 53 - 59.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
R. Bar-Shalom, N. Yefremov, N. Haim, E. J. Dann, R. Epelbaum, Z. Keidar, D. Gaitini, A. Frenkel, and O. Israel
Camera-based FDG PET and 67Ga SPECT in Evaluation of Lymphoma: Comparative Study
Radiology, May 1, 2003; 227(2): 353 - 360.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
L. Kostakoglu, H. Agress Jr, and S. J. Goldsmith
Clinical Role of FDG PET in Evaluation of Cancer Patients
RadioGraphics, March 1, 2003; 23(2): 315 - 340.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu and S. J. Goldsmith
18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma
J. Nucl. Med., February 1, 2003; 44(2): 224 - 239.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Jerusalem, Y. Beguin, M. F. Fassotte, T. Belhocine, R. Hustinx, P. Rigo, and G. Fillet
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease
Ann. Onc., January 1, 2003; 14(1): 123 - 130.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
B. G.M. Durie, A. D. Waxman, A. D'Agnolo, and C. M. Williams
Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
J. Nucl. Med., November 1, 2002; 43(11): 1457 - 1463.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
M Schwaiger
Functional imaging for assessment of therapy
Br. J. Radiol., November 1, 2002; 75(90009): S67 - 73.
[Full Text] [PDF]

Home page
 Ann OncolHome page
K. Spaepen, S. Stroobants, P. Dupont, P. Vandenberghe, J. Thomas, T. de Groot, J. Balzarini, C. De Wolf-Peeters, L. Mortelmans, and G. Verhoef
Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
Ann. Onc., September 1, 2002; 13(9): 1356 - 1363.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
O. Israel, M. Mor, D. Gaitini, Z. Keidar, L. Guralnik, A. Engel, A. Frenkel, R. Bar-Shalom, and A. Kuten
Combined Functional and Structural Evaluation of Cancer Patients with a Hybrid Camera-Based PET/CT System Using 18F-FDG
J. Nucl. Med., September 1, 2002; 43(9): 1129 - 1136.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
L. Kostakoglu, M. Coleman, J. P. Leonard, I. Kuji, H. Zoe, and S. J. Goldsmith
PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin's Disease
J. Nucl. Med., August 1, 2002; 43(8): 1018 - 1027.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
V. J. Lowe and G. A. Wiseman
Assessment of Lymphoma Therapy Using 18F-FDG PET
J. Nucl. Med., August 1, 2002; 43(8): 1028 - 1030.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. A. D'Amico, T. Z. Wong, D. H. Harpole, S. D. Brown, and R. E. Coleman
Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies
Ann. Thorac. Surg., July 1, 2002; 74(1): 160 - 163.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Lones, S. L. Perkins, R. Sposto, N. Tedeschi, M. E. Kadin, C. R. Kjeldsberg, J. F. Wilson, D. L. Zwick, and M. S. Cairo
Non-Hodgkin's Lymphoma Arising in Bone in Children and Adolescents Is Associated With an Excellent Outcome: A Children's Cancer Group Report
J. Clin. Oncol., May 1, 2002; 20(9): 2293 - 2301.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Trojan, M. Jermann, C. Taverna, and T. F. Hany
Fusion PET-CT imaging of neurolymphomatosis
Ann. Onc., May 1, 2002; 13(5): 802 - 805.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online